2023 International HBV Meeting

2023年国际乙型肝炎会议

• 批准号: 10753905
• 负责人: JOHN E TAVIS
• 金额: $ 0.7万
• 依托单位: HEPATITIS B FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-12 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10753905
• 关键词: Achievement; Affect; Animal Model; Animals; Antiviral Therapy; Award; Basic Science; Biochemistry; Biology; Biomedical Research; Cell model; Cellular biology; Cessation of life; Chronic; Chronic Hepatitis B; Clinical Research; Collaborations; Communities; Data; Development; Disadvantaged minority; Disease; Effectiveness; Ensure; Epidemic; Far East; Financial Support; Foundations; Funding; Gene Expression; General Population; Goals; Grant; Hepatitis B; Hepatitis B Vaccines; Hepatitis B Virus; Hepatitis Delta Virus; Human; Immunology; In Vitro; Industrialization; Infection; International; Investigational Therapies; Japan; Liver Cirrhosis; Liver Failure; Liver diseases; Malignant neoplasm of liver; Mission; Molecular; Molecular Biology; National Cancer Institute; National Institute of Allergy and Infectious Disease; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Oral; Pathogenesis; Persons; Postdoctoral Fellow; Primary carcinoma of the liver cells; Public Health; RNA Editing; Reagent; Recording of previous events; Regulator Genes; Reporting; Research; Research Personnel; Resources; Scientist; Senior Scientist; Students; Technology; Time; Travel; Underrepresented Minority; United States National Institutes of Health; Viral; Virus; Virus Diseases; anti-hepatitis B; career; chronic infection; community engagement; cost; curative treatments; disadvantaged background; drug development; effective therapy; gene therapy; graduate student; in vivo; interest; lectures; liver development; low and middle-income countries; meetings; minority investigator; new technology; novel strategies; novel therapeutic intervention; pathogen; patient oriented; posters; posttranscriptional; prevent; programs; prophylactic; protein expression; success; symposium; therapeutic siRNA; therapy development; tool; vector; virology; virus related cancer

ABSTRACT/SUMMARY Hepatitis B virus (HBV) is a major global public health threat with approximately 296 million chronically infected people worldwide and over 800,000 deaths per year. Chronic HBV infection is a leading cause for development of liver cirrhosis and hepatocellular carcinoma. Despite the effectiveness of the prophylactic HBV vaccine, it has no impact on established chronic infections. Consequently, there is a great need to discover new therapeutic strategies to cure chronic HBV infection and slow or stop the resulting disease. The annual International HBV Meeting is the only forum that gathers the international community of researchers who study infection, persistence, pathogenesis, and drug development for HBV and the closely associated hepatitis delta virus (HDV). This International HBV Meeting has been held yearly since 1985. In 2023, this meeting will be held for the first time in Japan, in East Asia where chronic hepatitis B is highly endemic, with over 100 million people chronically affected. Success of the International HBV Meeting relies on the contributions of not only the established investigators, but importantly, also on early career researchers from diverse backgrounds. To facilitate the participation of young scientists, we request funding to support travel expenses for early career and under- represented researchers at the 2023 International HBV Meeting. This 2023 meeting will provide the opportunity for scientific exchange and dissemination of the latest research information to discover new strategies for potentially curing HBV and HDV. An estimated 500-600 delegates will attend the 2023 meeting. The meeting will consist of 10 oral scientific sessions, 2 poster sessions, 3 plenary lectures from experts outside of the HBV field who will bring different perspectives, and a lecture given by the recipient of the Distinguished Award in HBV Research that is awarded annually by the meeting. Toward the goal of curing HBV and HDV, this meeting will be satellited by HBV cure symposium to discuss mechanisms underlying durability of anti-HBV siRNA therapy, and by an HBV community forum where scientists from the HBV community engage with the general public, media, students and those affected by HBV to discuss HBV/HDV and the related diseases. As in the past, great effort has been made to minimize the cost of the meeting. A major strength of the meeting organization being continual support from the Hepatitis B Foundation since 2005. In order to enable and facilitate participation of early career researchers and under-represented minority investigators to maximize the significance of the meeting, we request support from the National Institutes of Health to help defray their travel costs. This funding will be used to ensure attendance and presentation by early career researchers, particularly from low and middle-income countries, as well as disadvantaged and under-represented minority investigators.

摘要/总结 B肝炎病毒（HBV）是一种主要的全球公共卫生威胁，约有2.96亿人慢性感染 全球感染人数每年超过80万。慢性HBV感染是导致 发展为肝硬化和肝细胞癌。尽管预防性HBV的有效性 疫苗，它对已建立的慢性感染没有影响。因此，非常需要发现新的 治疗策略，以治愈慢性HBV感染和减缓或停止所产生的疾病。 一年一度的国际乙肝会议是唯一的论坛，聚集了国际社会， 研究HBV感染、持续性、发病机制和药物开发的研究人员， 丁型肝炎病毒（HDV）。国际乙肝大会自1985年以来每年举行一次。在2023年， 这次会议将首次在日本举行，在东亚，慢性B型肝炎是高度流行的， 超过1亿人长期受到影响。 国际乙肝会议的成功不仅取决于既定的 研究人员，但重要的是，也对来自不同背景的早期职业研究人员。方便 青年科学家的参与，我们要求资助，以支持旅行费用的早期职业生涯和下， 代表研究人员参加2023年国际HBV会议。2023年的会议将提供 科学交流和传播最新研究信息的机会， 可能治愈HBV和HDV的策略。预计将有500-600名代表参加2023年的会议。 会议将包括10个口头科学会议，2个海报会议，3个来自外部专家的全体讲座 HBV领域的谁将带来不同的观点，并由杰出的收件人所给的讲座 HBV研究奖每年由会议颁发。为了达到治愈HBV和HDV的目标， 会议将由HBV治愈研讨会卫星，讨论抗HBV持久性的机制 siRNA疗法，并通过HBV社区论坛，来自HBV社区的科学家参与其中， 公众、媒体、学生和受HBV影响的人讨论HBV/HDV和相关疾病。 同过去一样，为尽量减少会议费用作出了巨大努力。一个主要的优势， 自2005年以来，会议组织一直得到B型肝炎基金会的持续支持。为了使和 促进早期职业研究人员和代表性不足的少数民族调查人员的参与， 鉴于这次会议的重要性，我们请求美国国立卫生研究院提供支持，以帮助支付他们的旅费 成本这笔资金将用于确保早期职业研究人员的出席和演讲，特别是 来自低收入和中等收入国家以及处境不利和代表性不足的少数群体调查员。